Interní Med. 2019; 21(5): 266-269
Advances in biological treatment for severe asthma
- Oddělení alergologie a klinické imunologie, Fakultní nemocnice Olomouc
- Ústav imunologie Lékařské fakulty Univerzity Palackého v Olomouci
Bronchial asthma is a heterogeneous disease with a range of phenotypes and endotypes, which require a different therapeutic approach, especially in the case of severe forms of asthma that are refractory to standard therapy. Severe refractory asthma represents a serious problem with high morbidity and mortality of patients, and as a considerable health care burden. Introduction of biological therapy, which targets allergic and non-allergic eosinophilic asthma, represents a significant progress in the treatment of severe asthma. Monoclonal antibodies are already used in common practise against immunoglobulin E and interleukin-5, and more recently, monoclonal antibodies that target interleukin-4 and 13 have been introduced into the treatment of severe eosinophilic asthma. Other forms of biological therapy are in various stages of clinical development, whereas the treatment of severe non-eosinophilic asthma still remains the greatest therapeutic problem.
Keywords: severe asthma, biological treatment, anti‑IgE, anti‑IL-5, anti‑IL-4/IL-13
Published: December 1, 2019 Show citation
